News
Clinical Trials Arena on MSN14h
Astellas and Pfizer’s Xtandi combo reduces death risk in prostate cancer trialAstellas and Pfizer's Xtandi plus ADT showed a decrease in mortality risk in a metastatic hormone-sensitive prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback